Sugi Predict

Sugi Predict / Compounds / SCHEMBL1483347

SCHEMBL1483347

SCHEMBL1483347

Nc1nncc2cccn12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.40
▸ ALDH1A1 P00352 6/20 0.40
▸ HSD17B10 Q99714 3/20 0.40
▸ HPGD P15428 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 2/20 0.36
▸ MAPK14 Q16539 2/20 0.36
▸ CHEK1 O14757 1/20 0.36
▸ LIMK1 P53667 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MEN1 O00255 4/20 0.33
▸ KMT2A Q03164 4/20 0.33
▸ RAB9A P51151 3/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ POLB P06746 1/20 0.32
▸ PIM1 P11309 2/20 0.31
▸ KDR P35968 2/20 0.31
▸ FLT3 P36888 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1155383 0.75 KDM4E (0.40) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL19153363 0.75 KDM4E (0.40) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL334476 0.72 KDM4E (0.55) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL30214863 0.71 ALDH1A1 (0.37) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL18237720 0.71 KDM4E (0.37) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL398626 0.68 MAP2K2 (0.41) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL14776849 0.65 AKT2 (0.41) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL399440 0.62 CHEK1 (0.32) CHEK1KDRMAP4K4PRKACACDK8
SCHEMBL24377487 0.61 ALDH1A1 (0.47) KDM4EALDH1A1HSD17B10HPGDGLA
SCHEMBL558515 0.61 KDM4E (0.55) KDM4EALDH1A1HSD17B10HPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118302417-A NLRP3 inhibitors PTC医疗公司 2024-07-05 — — CN claimed
CN-118302417-A NLRP3 inhibitors PTC医疗公司 2024-07-05 — — CN disclosed
EP-4392414-A1 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-07-03 — — EP disclosed
WO-2023028534-A1 INHIBITORS OF NLRP3 PTC THERAPEUTICS, INC. (US) 2023-03-02 — — WO disclosed
US-20170349593-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-12-07 — — US disclosed
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US disclosed
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US disclosed
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US disclosed
US-8653268-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-02-18 — — US disclosed
US-8653268-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-02-18 — — US disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
US-20080253988-A1 Pyrrolo [1,2-D] [1,2-4] Triazine as Inhibitors of C-Jun N Terminal Kinases (Jnk) and P-38 Kinases NOVARTIS AG (CH) 2008-10-16 — — US disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 — — US disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 — — US disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 — — US disclosed
WO-2007064993-A2 BICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-06-07 — — WO disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080253988-A1 Pyrrolo [1,2-D] [1,2-4] Triazine as Inhibitors of C-Jun N Terminal Kinases (Jnk) and P-38 Kinases MAPK8, MAP3K8, STK38 KDM4E 2557/4885ALDH1A1 3728/4885HSD17B10 4504/4885
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 KDM4E 2218/4885ALDH1A1 3941/4885HSD17B10 4125/4885
US-20070149521-A1 Bicyclic protein kinase inhibitors CDK1, MAP4K2, MAP4K3 KDM4E 1338/4885ALDH1A1 4394/4885HSD17B10 3802/4885
US-20170349593-A1 BTK INHIBITORS BTK, SYK, LYN KDM4E 935/4885ALDH1A1 4251/4885HSD17B10 3212/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 KDM4E 2218/4885ALDH1A1 3941/4885HSD17B10 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.